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Abstract: Despite the introduction of new therapies for multiple myeloma (MM), many patients
are still dying from this disease and novel treatments are urgently needed. We have designed a
novel hybrid molecule, called NEO214, that was generated by covalent conjugation of the natural
monoterpene perillyl alcohol (POH), an inducer of endoplasmic reticulum (ER) stress, to rolipram
(Rp), an inhibitor of phosphodiesterase-4 (PDE4). Its potential anticancer effects were investigated in
a panel of MM cell lines. We found that NEO214 effectively killed MM cells in vitro with a potency
that was over an order of magnitude stronger than that of its individual components, either alone
or in combination. The cytotoxic mechanism of NEO214 involved severe ER stress and prolonged
induction of CCAAT/enhancer-binding protein homologous protein (CHOP), a key pro-apoptotic
component of the ER stress response. These effects were prevented by salubrinal, a pharmacologic
inhibitor of ER stress, and by CHOP gene knockout. Conversely, combination of NEO214 with
bortezomib, a drug in clinical use for patients with MM, resulted in synergistic enhancement of MM
cell death. Combination with the adenylate cyclase stimulant forskolin did not enhance NEO214
impact, indicating that cyclic adenosine 3′,5′-monophosphate (AMP) pathways might play a lesser
role. Our study introduces the novel agent NEO214 as a potent inducer of ER stress with significant
anti-MM activity in vitro. It should be further investigated as a potential MM therapy aimed at
exploiting this tumor’s distinct sensitivity to ER stress.
Keywords: bortezomib; CHOP; perillyl alcohol; phosphodiesterase; rolipram
1. Introduction
Among the various tasks of the endoplasmic reticulum (ER) is proper protein folding and
processing. A variety of physiological and pathophysiological conditions, as well as a number
of pharmacological agents, are able to disturb this process, thereby causing ER stress. The cell
reacts to ER stress by initiating a defensive process, called the unfolded protein response (UPR),
which pursues two objectives: first, in the case of moderate stress, the defensive module of this
system attempts to neutralize or adapt to the insult and restore proper homeostasis. Second, in the
case of excessively aggravated stress, the UPR switches to its pro-apoptotic module and initiates
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apoptosis [1]. Among the executor proteins of the apoptotic component is CHOP (CCAAT/enhancer
binding protein homologous transcription factor, also called GADD153), a transcription factor that
alters the transcriptional profile of cells and triggers a pro-apoptotic program [2]. Prolonged expression
of CHOP is a key trigger for apoptosis, and therefore this protein is commonly used as a marker to
indicate that pro-apoptotic events of the UPR have been initiated [3].
Chronically elevated levels of ER stress have been implicated in a number of diseases, and efforts
are underway to develop approaches to target ER stress mechanisms for therapy. For example, obesity
and type 2 diabetes have been linked to ER stress-induced failure of insulin-producing pancreatic beta
cells, and current research efforts are aimed at developing drugs that ameliorate cellular stress and
thereby protect beta cell function [4,5]. The opposite approach is being investigated in the context
of cancer therapy. Here, research efforts aim at further aggravating pre-existing ER stress, seeking
to reach the pro-apoptotic threshold to initiate cell death [6]. Secretory cancer cells, such as multiple
myeloma (MM), are attractive targets for this approach, because in addition to the general demands
of proliferating cancer cells, these cells highly depend on proper ER functioning for their extensive
immunoglobulin production [7].
Treatment options for MM have increased over the past 10 years and have resulted in improved
survival rates among MM patients. However, there is a high relapse rate, and the disease remains
incurable in many cases [8]. Bortezomib, the first of several clinically used proteasome inhibitors,
is used across the entire spectrum of myeloma disease, either as single agent or combined with other
therapies [9]. Inhibition of proteasome function by bortezomib results in the accumulation of normal
proteins that were bound for destruction and of misfolded, unfolded, and otherwise damaged proteins.
This accumulation of superfluous proteins triggers ER stress and causes effective stimulation of the
pro-apoptotic UPR module, in particular prolonged expression of CHOP, resulting in proteotoxic cell
death [10,11]. In this context, ER stress has been considered the Achilles’ heel of MM [12].
We have been studying approaches to further aggravate chronic ER stress in cancer cells in
order to achieve optimized tumor cell killing. We showed previously that certain combinations of ER
stress-aggravators (ERSAs), i.e., pharmacological agents that aggravate low-level, chronic ER stress that
exists in tumor cells, result in superior anticancer outcomes in vitro and in vivo [6,13]. For example,
we demonstrated that the combination of bortezomib with the cyclooxygenase-2 (COX2) inhibitor
celecoxib potently aggravated ER stress and resulted in strongly enhanced tumor cell death [14].
Others have shown potent combination effects of bortezomib and the HIV-1 protease inhibitor
nelfinavir, which also is known to trigger pro-apoptotic ER stress [15,16]. In the current study, we have
further explored the principle of aggravating ER stress and have created a novel hybrid molecule with
potent ERSA characteristics. This molecule, called NEO214, consists of two pharmacologically distinct
compounds, rolipram (Rp) and perillyl alcohol (POH).
Rp is a selective phosphodiesterase-4 (PDE4) inhibitor that was in clinical development as an
anti-depressant in the early 1990s. However, clinical trials revealed that it required fairly high dosing
that resulted in the emergence of significant side effects, primarily dose-limiting gastrointestinal
(GI) toxicities, and therefore it was abandoned [17]. More recently, efforts have started to repurpose
Rp for cancer therapy and other applications. For example, it was demonstrated in vitro that Rp
could inhibit proliferation of cancer cell lines derived from different cancer types [18–22]. In vivo, Rp
was shown to slow intracranial glioblastoma growth when added to first-line therapy consisting of
temozolomide and radiation [23]. Among the various non-cancer applications being explored for Rp is
its neuroprotective function, which has shown significant benefit in mouse models of traumatic spinal
cord injury [24].
Perillyl alcohol (POH) is a monoterpene and a natural constituent of lavender and lilac oil,
cherries, cranberries, spearmint, and certain other plants [25]. Although this compound had shown
promising activity in several preclinical cancer models, it did not enter clinical practice, primarily
because dose-limiting GI toxicity became evident in clinical trials with oral POH [26]. However, recent
phase I/II clinical studies in Brazil indicated that simple intranasal inhalation of POH was effective
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against recurrent glioblastoma, in the absence of detectable toxic events [27], and similar clinical
studies have started in the United States (NCT02704858).
The molecular mechanism of action of POH is not entirely clear. Initially, it was characterized
as an inhibitor of Ras oncoprotein [28,29], but a number of experimental models have challenged
this view [30–32]. Additional identified POH targets include c-fos and c-jun proto-oncogenes [33],
transforming growth factor beta (TGFβ) receptor [34], nuclear factor kappa B (NF-κB) [35], mammalian
target of rapamycin (mTOR) [36], components of the cell cycle machinery [37,38], and certain
cellular enzymes, such as telomerase [39,40] and sodium/potassium adenosine triphosphatase
(Na/K-ATPase) [41]. Altogether, it is likely that POH exerts pleiotropic impact on several of these
targets simultaneously, and at least some of them result in aggravated ER stress [42], cell cycle arrest [34]
and/or induction of apoptosis [43] (see further details and additional references in recent review: [26]).
We have created a novel molecule, NEO214, where POH was covalently conjugated to Rp. Initially,
the idea behind this approach was to devise a chimeric chemotherapeutic agent that potentially might
be suitable for intranasal delivery, thus avoiding the limitations due to GI toxicity after oral delivery.
Here we report on the in vitro characterization of NEO214’s biological activity and ability to trigger
tumor cell death and present evidence of its molecular mechanism of action, which involves potent
ERSA activity.
2. Results
2.1. Cytotoxic Potency of NEO214 is Greater Than the Sum of Its Parts
Rp and POH were covalently conjugated via a carbamate bridge to create the novel chemical
entity NEO214 (Figure 1). The cytotoxic in vitro activity of NEO214 was studied in five different
human MM cell lines, RPMI/8226, U266, H929, ARH-77, and Hs-Sultan. Cells were incubated
with increasing concentrations of NEO214 for 48 h, and cell viability was determined by standard
Methylthiazoletetrazolium (MTT) assay. As presented in Figure 2A, all cells were similarly sensitive to
killing by NEO214, with an IC50 of about 50 µM. Importantly, 8226/Dox40 cells, a multidrug-resistant
variant of the RPMI/8226 cells, were sensitive to NEO214 as well (Figure 2B). Repetitions of all MTT
assays at different cell densities and different incubation times yielded similar outcomes.
Figure 1. Chemical structure of NEO214. NEO214 was generated by covalently linking rolipram to
perillyl alcohol via a carbamate bridge (shown between dotted lines).
We next compared these effects to those of the individual constituents of NEO214, Rp and POH,
either alone or in combination. As shown in Figure 3 with RPMI/8226 and U266 cells, the application
of Rp alone or POH alone required 10–20 times higher concentrations in order to reach the cytotoxic
IC50. Intriguingly, an equimolar mix, consisting of Rp and POH as individual, non-conjugated
compounds, also was unable to mimic the strong cytotoxic potency of the conjugated compound.
Table 1 summarizes these comparisons for all 5 MM cell lines and the drug-resistant 8226/Dox40
line. As shown, the average cytotoxic IC50 values were in the range of 50–59 µM for NEO214,
whereas the values for Rp ranged from 551 µM to over 1 mM, and those of POH all were above
1 mM. Equimolar mixes of Rp plus POH as individual compounds yielded IC50s from 482–789 µM,
demonstrating that NEO214’s potency was an order of magnitude greater than the potency of the sum
of its parts.
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Figure 2. NEO214 kills multiple myeloma (MM) cells in vitro. Different MM cell lines were treated
at increasing concentrations of NEO214, and cell viability was determined 48 h later by standard
Methylthiazoletetrazolium (MTT) assay. (A) U266, ARH-77, H929, and Hs-Sultan cells were used.
(B) RPMI/8222 and 8226/Dox40 cells were used. The right panel demonstrates very large differential
in response to doxorubicin treatment, confirming high drug-resistance status of the Dox40 subline.
Asterisks (***): statistical difference between data points ≥ 25 nM doxorubicin: p < 0.001). In all
cases, vehicle-only treated cells, as well as entirely untreated cells, were used as controls (there was no
difference between the two). Survival of untreated cells was set at 100%. Data points are mean ± SE
from ≥3 independent experiments.
Figure 3. NEO214 is more cytotoxic than the sum of its parts. RPMI/8226 and U266 cells were treated
with increasing concentrations of NEO214, Rolipram (Rp), perillyl alcohol (POH), or an equimolar
mix of Rp plus POH. Cell survival was determined 48 h later by MTT assay. Survival of vehicle-only
treated cells was set at 100%. Data points are mean ± SE from ≥3 independent experiments.
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In comparison to these cancer cell lines, we also determined the effects of NEO214 on non-tumor
cells from other tissues, i.e., immortalized breast epithelial cells, primary astrocytes, and primary
brain endothelial cells. As displayed in Table 1, in the case of immortalized cells, the IC50 of NEO214
approximately doubled, to an average of 118 µM. In the case of truly normal (i.e., non-immortalized)
primary cells, there was no detectable toxicity even at the highest concentrations of NEO214 used,
which was 200 µM. Thus, there was a clear, statistically significant (p < 0.01) difference in NEO214
sensitivity between the above MM cell lines and the tested non-tumor cells, suggesting that NEO214
perhaps could be clinically useful.
Table 1. Drug sensitivities of various human cell types.
Cells Cell Type NEO214 Rp POH Rp + POH p-Value *
RPMI/8226 MM 50 551 >1000 482 <0.0001
8228/Dox40 MM 59 n.d. n.d. n.d. <0.0001
U266 MM 56 >1000 >1000 606 <0.0001
ARH-77 MM 52 >1000 >1000 783 <0.0001
H929 MM 50 578 >1000 486 <0.0001
Hs-Sultan MM 55 >1000 >1000 789 <0.0001
ME16C normal breast 118 ** n.d. n.d. n.d. n.d.
Astrocytes normal brain >>200 *** n.d. n.d. n.d. n.d.
BEC brain endothelial >>200 *** n.d. n.d. n.d. n.d.
Shown are average IC50 values in µM (as determined by MTT assay). n ≥ 3. * p-Value: statistical difference between
treatment with NEO214 and any of the three other conditions (Rp, POH, Rp + POH). ** p < 0.01 for difference
between MM cancer cells and immortalized normal breast epithelial cells. *** 200 µM was the highest concentration
tested and there was no detectable toxicity in these normal primary cells. n.d.: not determined. ME16C, mammary
gland epithelial cells; BEC, brain endothelial cells.
2.2. NEO214 Inhibits Phosphodiesterase 4
To gain insight into the mechanisms of NEO214-induced cell death, we focused on the
two processes that were known to be targeted by its individual components, i.e., inhibition of PDE4
enzymatic activity by Rp and aggravation of ER stress by POH. First, the in vitro activity of purified,
recombinant PDE4 was determined in the presence of NEO214, Rp, or piclamilast (a PDE4-specific
inhibitor). As shown in Figure 4A, all three compounds demonstrated potent PDE4-inhibitory activity
at very similar IC50s in the sub-micromolar range. It therefore appeared that Rp’s inhibitory potency
was faithfully retained within the NEO214 molecule.
As an approach to determine whether inhibition of PDE4 might be critical to mediating NEO214’s
cytotoxic impact, we treated cells with NEO214 in the presence or absence of forskolin (FSK).
Our rationale was that stimulation of adenylate cyclase activity with FSK should greatly enhance
any potential cytotoxic effects initiated by inhibition of PDE4 with NEO214, due to more effective
accumulation of cyclic AMP. However, the results presented in Figure 4B do not appear to support
this view. We found that the addition of FSK did not substantially increase overall cytotoxic impact
over that which would be expected from the sum of these two compounds. FSK at 1 or 3 µM
was unable to increase cytotoxic activity of NEO214 alone; FSK at 10 µM exerted some toxicity by
itself (~15% reduction of viability) and in combination with NEO214 enhanced overall toxicity by
approximately this margin (Figure 4B). Therefore, these results did not point to a major role of cyclic
AMP signaling or PDE4 inhibition in mediating NEO214’s anticancer effects.
Int. J. Mol. Sci. 2018, 19, 277 6 of 18
Figure 4. In vitro PDE4 activity and combination with forskolin. (A) The enzymatic activity of purified,
recombinant PDE4A1A was determined in the presence of increasing concentrations of rolipram (Rp),
NEO214, or piclamilast (PIC). Data shown are averages from two independent repeats, each one
performed in duplicate. (B) RPMI/8226 cells were treated with combinations of NEO214 and forskolin
(FSK). After 48 h, cell viability was determined by MTT assay. Survival of vehicle-only treated cells
was set at 100%. Data points are mean ± SE from two experiments with each data point in triplicate.
2.3. NEO214 Triggers Pro-Apoptotic ER Stress
To gain further insight into the mechanisms of NEO214-induced cell death, we next investigated
several established markers as readouts of specific cellular processes. The expression level of activating
transcription factor 3 (ATF3) was used as a general cell stress indicator. CHOP was used as the
well-characterized marker of activation of the pro-apoptotic module of the ER stress response/UPR.
In addition, we analyzed typical markers of apoptosis, specifically the proteolytic cleavage of PARP
(poly-ADP-ribose polymerase), the activation of caspase 7 (C-7), and emergence of phosphorylated
HA2X protein (γ-HA2X, indicating damage and degradation of DNA).
RPMI/8226 cells were treated with different concentrations of NEO214 and for different time
points. Figure 5A shows that NEO214 triggered pronounced activation of all these markers, signifying
severe cellular stress and ensuing apoptosis. Importantly, increased levels of CHOP could be detected
fairly early, at 8 h, and did not diminish even at 40 h, indicating that the pro-apoptotic cellular
response was maintained and could not be subdued by the pro-survival/adaptive module of the
UPR. This observation was further supported by continuously increasing levels of apoptotic markers,
activated caspase 7, cleaved PARP, and γ-HA2X. Nearly identical results were also obtained with U266
cells, confirming the observations in a different cell line (Figure 5B).
Because increased CHOP expression indicated severe ER stress, we also determined expression
levels of cyclin D1, a cell cycle protein essential for cell proliferation. A well characterized feature
of ER stress is inhibition of cellular protein synthesis (with select exception of stress proteins such
as ATF3, CHOP and others), and therefore short-lived proteins like cyclins will quickly disappear
from the cell’s protein inventory. This was indeed the case in response to treatment with NEO214:
treatment of U266 cells with NEO214 resulted in rapid disappearance of cyclin D1 protein (Figure 5B),
further revealing the presence of drug-induced ER stress. Notably, cyclin D1 expression did not recover
over 48 h, showing that the pro-survival module of the ER stress response was unable to subdue its
pro-apoptotic, CHOP-controlled component.
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Figure 5. NEO214 induces markers of ER stress and apoptosis. (A) RPMI/8226 cells were treated
with increasing concentrations of NEO214 for 24 h (left panel) or with 100 µM NEO214 for different
times (right panel). (B) U266 cells were treated with 100 µM NEO214 for different times, and with
vehicle only (vh.) for 48 h. In all cases, cell lysates were prepared and subjected to Western blot
analysis with specific antibodies as indicated. Actin was used as the loading control. cl. C-7: cleaved
caspase 7 (band represents active fragment). Two arrows point to full-length and cleaved form of
poly-ADP-ribose polymerase (PARP). CHOP, CCAAT/enhancer-binding protein homologous protein;
ATF3, activating transcription factor 3, γH2AX, phosphorylated form of histone variant H2AX protein.
As our cytotoxicity assays had shown that the individual components of NEO214—Rp and
POH—were unable to mimic the strong cytotoxic potency of the conjugated compound, we next
investigated whether this would also hold true with regard to the above protein markers of stress
and apoptosis. RPMI/8226, 8226/Dox40, and U266 cells were treated with Rp alone, POH alone,
or Rp combined with POH at equimolar concentrations, and the readouts were compared to those of
NEO214 treatment. When used at 100 µM, treatment of these cells with Rp, POH, or Rp plus POH
did not result in any detectable increase of the investigated stress markers or any of the apoptotic
indicators (Figure 6). In comparison, NEO214 at the same concentration triggered a strong response,
including in multidrug-resistant 8226/Dox40 cells. Further increased concentrations for combination
treatments, where 300 µM Rp was mixed with 300 µM POH, also did not result in an appreciable
response. Only when 1000 µM Rp was combined with 1000 µM POH was an effect observed (Figure 6,
left panel). Thus, with regard to the prominent induction of stress markers and apoptotic indicators,
NEO214 was about 10–20-fold more potent than the sum of its parts, i.e., the combination of Rp
plus POH.
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Figure 6. NEO214 is more potent than the sum of its parts. RPMI/8226, 8226/Dox40, and U266 cells
were treated with Rp alone, POH alone, and Rp plus POH in combination, at the indicated concentrations.
For comparison purposes, cells were also treated with NEO214 in parallel. Control cells remained untreated
(left lane in each panel) or were treated with vehicle (lanes marked by asterisk: *). After 24 h, cell lysates
were prepared and subjected to Western blot analysis with actin as the loading control. Note effective
induction of stress markers (CHOP and ATF3) and apoptosis markers (cleaved/active caspase 7, PARP
and γ-HA2X) by 0.05 and 0.1 mM NEO214, whereas Rp and POH, alone or in combination, did not affect
expression of these markers, unless their concentrations were increased to 1 mM each (left panel). (Due to
the high concentrations included, drug concentrations in this figure are shown in units of millimolar).
2.4. ER Stress and CHOP are Key to NEO214-Induced Cell Death
We next investigated the extent by which NEO214-induced ER stress contributed to ensuing cell
death. We used salubrinal, an established inhibitor of cellular ER stress processes. MM cells were treated
with NEO214 in the presence or absence of salubrinal, and cell viability was determined by MTT assay.
As presented in Figure 7, salubrinal was able to potently blunt the toxic impact of NEO214 in both
RPMI/8226 and U266 cells, as indicated by significantly (p < 0.001) increased cell survival in the presence
of this ER stress inhibitor. Salubrinal’s protective effect could be validated at the molecular level as well.
As shown in Figure 8, the presence of salubrinal prevented NEO214-induced CHOP expression, activation
of caspase 7, cleavage of PARP, H2AX phosphorylation, and downregulation of cyclin D1. Together,
these data indicate that NEO214 requires aggravation of ER stress in order to effectively trigger apoptosis.
Figure 7. Salubrinal antagonizes NEO214 toxicity. RPMI/8226 and U266 cells were treated with
increasing concentrations of NEO214 in the presence or absence of 75 µM salubrinal. After 48 h, cell
viability was determined by standard MTT assay. Similar results were obtained at 24 h and at 72 h.
Asterisks (***): p < 0.001 between salubrinal and vehicle at NEO214 concentrations ≥ 50 µM.
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To further investigate the role of CHOP in NEO214-induced cell death, we utilized a pair of
well-characterized mouse embryo fibroblasts (MEF), consisting of wild type cells and a CHOP-knockout
(KO) variant. These cells were exposed to NEO214, followed by the analysis of cell survival by MTT
assay and expression levels of key protein markers by Western blot. As shown in Figure 9A, NEO214
treatment of wild type MEF cells resulted in an outcome similar to what was observed in MM cells:
there was strong induction of CHOP and potent activation of caspase 7 with pronounced cleavage of
PARP. In contrast, CHOP-KO cells lacked CHOP induction and potent caspase 7 activation; expression
of full-length PARP protein was strongly elevated, but there was less cleavage as compared to wild
type cells. At the same time, there was significantly (p < 0.01) increased cell survival in CHOP-KO
cells, although lack of CHOP protein did not completely protect cells from NEO214-induced cell death
(Figure 9B). Altogether, these results point to a key role of CHOP in mediating apoptosis induced by
NEO214, although other components might contribute as well.
Figure 8. Salubrinal prevents NEO214-induced ER stress and apoptosis. (A) RPMI/8226 cells were
treated with or without 100 µM NEO214 in the presence or absence of 75 µM salubrinal (Sal) for 24 h.
In parallel, 50 µM cycloheximide was included as a positive control for inhibition of protein synthesis
and resulting apoptosis. (B) U266 cells were treated with or without NEO214 in the presence or absence
of salubrinal for different times. In all cases, lysates were prepared and subjected to Western blot
analysis with specific antibodies as indicated. Actin was used as the loading control. Cyc D1: cyclin
D1; cl. C-7: cleaved/activated caspase 7. Two arrows point to full-length and cleaved form of PARP.
vh.: vehicle.
Figure 9. NEO214 requires CHOP for effective cytotoxic impact. Wild type or CHOP knockout (CHOP-KO)
mouse embryo fibroblasts (MEF) were treated with NEO214 and analyzed. (A) Cells were treated with
150 µM NEO214 for different times, and cell lysates were analyzed by Western blot. (B) Cells were treated
with increasing concentrations of NEO214 for 48 h, followed by determination of cell viability by MTT
assay. Asterisks (**): p < 0.01 between wild type and CHOP-KO cells at NEO214 concentrations≥ 80 µM.
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2.5. NEO214 Synergizes with Bortezomib
As bortezomib represents the standard of care for MM patients, we next investigated the effects
of NEO214 in combination with this proteasome inhibitor. RPMI/8226 cell survival was investigated
by MTT assay, and protein markers of cellular stress and apoptosis were determined by Western
blot. Figure 10A shows that addition of NEO214 was able to significantly enhance cell death
induced by bortezomib. As well, induction of stress markers (ATF3, CHOP) and apoptotic indicators
(cleaved caspase 7, PARP and γ-HA2X) was stronger in response to combination treatments as
compared to individual treatments with NEO214 or bortezomib. For example, while 5 nM bortezomib
or 40 µM NEO214 individually triggered only weak induction of these markers, their combination
resulted in much more pronounced effects.
We also determined cell survival during combination treatments. Figure 10B shows results from
MTT assays after treatment of cells with increasing concentrations of NEO214 (0–60 µM) combined with
increasing concentrations of bortezomib (0–6 nM). Cell death resulting from combination treatments was
much more severe than from individual treatments, in particular when bortezomib concentrations were
increased from 2 to 4 and 6 nM. To formally establish whether these effects were synergistic, the data were
subjected to statistical analysis based on the Bliss independence model [44]. These calculations showed
that combination treatments that included 2 nM bortezomib resulted in additive toxicity, but combination
treatments with 4 or 6 nM bortezomib—which represent concentrations that are readily achievable in
patients [45]—generated strongly synergistic outcomes (Figure 10C). Comparable synergistic outcomes
were achieved with U266 cells as well, emphasizing that the enhanced combination effects are not limited
to the RPMI/8226 cell line but might be generally applicable to MM.
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Figure 10. NEO214 synergizes with bortezomib. RPMI/8226 cells were treated with NEO214 alone, bortezomib (BZM) alone, or both in combination. (A) Top panel shows
cell viability after 48 h of treatment, as determined by MTT assay. Bottom panel shows expression levels of ER stress markers and indicators of apoptosis after 24 h of
treatment, as determined by Western blot analysis. Note that the effects of BZM alone on several of these markers were fairly weak, but were substantially enhanced in the
presence of NEO214. (B) Percent cell death in response to increasing concentrations of BZM (0–6 nM) combined with increasing concentrations of NEO214 (0–60 µM) after 48
h, as determined by MTT assay (averages from six measurements). (C) Statistical analysis of drug combination effects of BZM plus NEO214. Dotted red line represents
the predicted (i.e., calculated) combination effect (YP) based on the Bliss independence model, which signifies additive effect. Blue straight line shows the observed (i.e.,
measured) combination response (YO). Overlap of blue line with red line in top graph indicates additive effects at 2 nM BZM. Higher BZM concentrations (4 and 6 nM,
middle and bottom panels) result in separation of the lines and pronounced left-shift of blue line, indicating strong synergistic effects. Similar effects were also obtained with
U266 cells.
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3. Discussion
The ER stress response/UPR represents a recognized target for therapeutic intervention in
cancer, particularly in highly secretory cells such as MM. The clinically used proteasome inhibitor
bortezomib appears to exploit this target, at least in part, resulting in proteotoxic cell death [10,11].
Preclinical research efforts from us and others have indicated that it might be possible to achieve
superior therapeutic outcomes through the combination of suitable ER stress aggravating agents [6,12].
In this current study, we have explored a novel ERSA combination for MM, based on the use of a
newly created, chimeric molecule—NEO214—that turned out to harbor strong ERSA potency.
Intriguingly, covalent conjugation of Rp and POH resulted in a molecule with anticancer potency
that was substantially greater not only compared to Rp and POH individually, but also when
compared to equimolar combinations of Rp plus POH. In particular, when POH was mixed with
Rp for combination treatment, the resultant IC50 was lowered less than two-fold, as compared to
individual drug treatments. However, after covalent binding of POH to Rp, as NEO214, the IC50
was lowered by an order of magnitude, as compared to combination treatment with the individual
components (Table 1). This large differential was consistently observed in all cell lines investigated
and was not limited to cell death assays, but was also evident during the analysis of cellular stress
markers. For example, expression of ATF3 and CHOP proteins was readily stimulated by 50 µM
NEO214, whereas combinations of Rp plus POH required 1 mM of each compound to achieve a similar
effect (Figure 6). Quite clearly, the potency of NEO214 could not be mimicked by a mere mix of its
individual components, and thus the activity of the conjugated compound was substantially greater
than the sum of its parts.
We also tested NEO214 in normal cells. When added to immortalized, non-tumor cells,
the cytotoxic IC50 of NEO214 doubled. More impressively, when applied to truly normal, primary
human cells (astrocytes and endothelial cells), we were unable to detect toxic effects of NEO214 even at
the highest concentration used (Table 1). These findings are encouraging for the drug’s future clinical
testing. In prior clinical trials using oral dosing, both Rp and POH had shown toxicity, primarily
dose-limiting GI problems (nausea, vomiting, etc.), which resulted in discontinuation of further
development of these oral formulations [26,46]. In the case of POH however, switching from oral to
intranasal delivery offered a non-toxic alternative and yielded highly promising results in patients
with malignant glioma [27]. In a mouse model of chlorine-induced lung injury, it was demonstrated
that intranasal Rp was equally effective as intraperitoneally injected Rp [47], suggesting that—similar
to POH—intranasal delivery perhaps could be a less toxic alternative to oral delivery in the case of
Rp as well. While NEO214 has not been studied in humans, the above considerations serve as a
reminder that future clinical studies of NEO214 should consider its intranasal application, as has been
suggested for other chemotherapeutic interventions based on POH-conjugated agents that are under
development [48].
What are the cellular targets involved in mediating NEO214-induced cell killing? Prior studies
had indicated that stimulation of cyclic AMP signaling via Rp-mediated inhibition of PDE4 can
result in growth inhibition of tumor cells of hematopoietic origin, in particular chronic lymphocytic
leukemia (CLL), acute lymphocytic leukemia (ALL), and MM cells [49–51]. We therefore surmised
that PDE4-inhibitory activity of Rp, which was preserved in the chimeric NEO214 molecule (Figure 4),
might play a role. However, several points of evidence seem to argue against this model. For instance,
although PDE4-inhibitory potency of Rp and NEO214 against purified enzyme is the same (Figure 4A),
the cytotoxic potency of NEO214 is 10–20 fold greater than that of Rp (Table 1). Furthermore, if elevated
cyclic AMP levels played a key role, one would expect that addition of forskolin would greatly enhance
cell death triggered by PDE4 inhibition, as was demonstrated in other studies with ALL, CLL and
MM cell lines [49,50]. However, in our cell lines no such enhancement could be observed (Figure 4B).
While a convincing contribution of cyclic AMP signaling could not be established, we did however
collect substantial evidence supporting a key role for another central cellular process, namely ER stress.
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The potential contribution of ER stress was surmised on the basis of our earlier studies with POH,
which demonstrated that this monoterpene was able to kill glioblastoma cells at least in part through
aggravated ER stress, although fairly high concentrations approaching the millimolar range were
required [42]. In the current study, we demonstrate that NEO214 preserved the ER stress-aggravating
activity of POH, but at much increased potency. Our data revealed that NEO214 triggered severe ER
stress, as indicated by strongly stimulated expression of CHOP protein, the key indicator and central
executor of the pro-apoptotic module of the ER stress response system/UPR [2,3]. Although several
other components of this cellular stress system cooperate to orchestrate appropriate responses to stress,
CHOP has been shown to represent the master regulator that switches the cellular efforts from the
initial defensive attempts to subsequent apoptotic execution. In unstressed cells, CHOP levels are
generally undetectable or very low, and over-expression of this protein results in cell cycle arrest,
which is followed by cell death—unless the elevated expression can be reversed by the defensive
efforts of the UPR [3,52]. In our experimental system, we analyzed CHOP levels as a convenient
readout for pro-apoptotic ER stress in our experiments. We found that NEO214 resulted in powerful,
prolonged stimulation of CHOP expression that was not reversed (Figure 5). CHOP was prominently
elevated as early as 4 h after the onset of NEO214 treatment, and even at 48 h after the addition of
stimulus, CHOP levels remained very high. In parallel, apoptotic markers (activated caspase 7 and
cleaved PARP) began to appear at 4–8 h and continued to increase further over time. Altogether, this
mode of response was highly consistent with the dominant function of the pro-apoptotic module of ER
stress/UPR and the well-known pivotal role of CHOP [2,53], providing evidence that this mechanism
played a decisive role in mediating cell death induced by NEO214.
The key role of ER stress and CHOP was validated with salubrinal and CHOP-knockout cells.
Salubrinal acts as a phosphatase inhibitor, thereby preventing the dephosphorylation of eukaryotic
translation initiation factor 2 alpha (eIF2α) during the ER stress response [54]. Its cytoprotective effects
were established in a number of cellular stress conditions induced by various ER stress-aggravating
compounds [55,56]. In our experimental system, inclusion of salubrinal exerted cytoprotective effects
against NEO214 (Figures 7 and 8). Similarly, significant protection was also provided by knockout of
CHOP alleles, i.e., in cells where the pro-apoptotic arm of the ER stress response was at least partially
amputated (Figure 9). On the other hand, we noted that in both instances, protection was not complete,
and cell death still took place at much higher concentrations of NEO214. Therefore, while ER stress
and its pro-apoptotic master regulator CHOP clearly are key players in NEO214-induced cell death, it
is likely that other cellular components and mechanisms might contribute as well, although perhaps to
a lesser extent.
The ERSA principle is based on a model where tumor cells experience chronic ER stress
that can be exploited to overload the already engaged response system to exceed the tumor cells’
capacity for adaptation [6]. Due to their secretory phenotype, MM cells might be particularly
susceptible to an ERSA-based therapeutic approach, and bortezomib, at least in part, appears to
work by this principle [10,12]. Our present study advances this approach further by presenting a
novel pharmacological agent, NEO214, that can be applied to synergistically further aggravate the
bortezomib-primed system toward optimized tumor cell killing (Figure 10). Should these in vitro
synergistic outcomes be validated in the clinic, they would support the use of overall lower drug
dosages, which in the patient might result in fewer side effects and an overall higher quality of life
during cycles of treatment. While NEO214 has not yet been tested in the clinic, our present in vitro
studies do provide support for the above model and encouragement for its further investigation
toward clinical development.
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4. Materials and Methods
4.1. Pharmacological Agents
Rolipram, bortezomib, and forskolin were obtained from LC Laboratories (Woburn,
MA, USA). Perillyl alcohol, salubrinal, piclamilast, cycloheximide, and DMSO were from
Sigma-Aldrich (St. Louis, MO, USA). NEO214 was manufactured by Norac Pharma (Azusa,
CA, USA) and was provided by NeOnc Technologies, Inc. (Los Angeles, CA, USA).
Chemical purity was 99%, which was confirmed by 1H-NMR (300 MHz), mass spectrometry,
and microanalysis. The white solid was dissolved in DMSO at 100 mM, and aliquots
were stored at –80 ◦C. NEO214’s IUPAC name is ((S)-4-(prop-1-en-2-yl)cyclohex-1-enyl)methyl
4-(3-(cyclopentyloxy)-4-methoxyphenyl)-2-oxopyrrolidine-1-carboxylate and its CAS number is
1361198-80-2. Molecular formula is C27H35NO5 and molecular weight is 453.57 g/mol.
4.2. Cell Lines and Culture
The following human multiple myeloma cell lines were used: RPMI/8226 and U266 (purchased from
the American Tissue Culture Collection, ATCC, Manassas, VA, USA), and ARH-77, H929 and Hs-Sultan
(kindly provided by Alan Epstein, USC). We also used 8226/Dox40, which is a doxorubicin-resistant
subline of the RPMI/8226 cells [57]. All MM cell lines were propagated in RPMI-1640 medium
supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin, and 0.1 mg/mL streptomycin
in a humidified incubator at 37 ◦C and a 5% CO2 atmosphere. As representatives of normal human
cells, we used ME16C (mammary gland epithelial cells, immortalized with hTERT; from the ATCC),
primary cerebral cortex astrocytes (ScienCell, Carlsbad, CA, USA), and primary brain endothelial cells
(BEC), which were isolated and characterized as described previously [58]. ME16C cells were cultured
in DMEM supplemented as above, whereas astrocytes were grown in astrocyte medium. BEC were
cultured as described earlier [58]. Wild type mouse embryo fibroblasts (MEF wt) and CHOP-knockout
derivatives (both from the ATCC) were cultured in DMEM supplemented as above, with additional
0.1 mM non-essential amino acids. All cell culture reagents were provided by the Cell Culture Core Lab of
the USC/Norris Comprehensive Cancer Center and prepared with raw materials from Cellgro/MediaTech
(Manassas, VA, USA). FBS was obtained from Omega Scientific (Tarzana, CA, USA) and from X&Y Cell
Culture (Kansas City, MO, USA).
4.3. MTT Assay
Methylthiazoletetrazolium (MTT) assays were performed as described earlier [59]. Briefly, cells
were seeded into 96-well plates at 2–5 × 104 cells per well and exposed to drug treatment (or solvent
alone) for 24, 48, or 72 h. In individual experiments, each treatment condition was set up in triplicate,
and each experiment was repeated several times independently.
4.4. Immunoblots
Total cell lysates were analyzed by Western blot analysis as described earlier [60]. Antibodies were
obtained from Cell Signaling Technology (Danvers, MA, USA) and Santa Cruz Biotechnology
(Santa Cruz, CA, USA). All antibodies were used according to the manufacturers’ recommendations.
All immunoblots were repeated at least once to confirm the results.
4.5. Determination of Phosphodiesterase Activity
The inhibitory impact of different compounds on PDE4 enzymatic activity was measured with
the use of a PDE4A Assay Kit purchased from BPS Bioscience (San Diego, CA, USA). Following the
manufacturer’s instructions, purified PDE4A1A recombinant protein was incubated with or without
the compound to be tested, in the presence of fluorescently labeled cyclic AMP. After 1 hour at room
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temperature, a binding agent was added to produce a change in fluorescent polarization that was
measured using an Infinite M1000 microplate reader (Tecan, San Jose, CA, USA).
4.6. Calculation of Drug Combination Effects
Cells were treated with increasing concentrations of individual drugs, as well as their
combinations, and resulting cell toxicity was determined by MTT assay. Drug combination efficacy
was evaluated with the Bliss independence model [44], which focuses on treatment effect enhancement.
This method compares the observed combination response (YO) with the predicted combination
response (YP). Typically, the combination effect is declared synergistic if YO > YP, additive if YO = YP,
and antagonistic if YO < YP.
4.7. Other Statistical Analysis
All parametric data were analyzed using the Student t-test to calculate the significance values.
A probability value p < 0.05 was considered statistically significant.
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Abbreviations
ATF3 Activating transcription factor 3
BZM Bortezomib
CHOP CCAAT/enhancer-binding protein homologous protein (also called GADD153)
ER Endoplasmic reticulum
ERSA Endoplasmic reticulum stress aggravator
FSK Forskolin
γH2AX Phosphorylated form of histone variant H2AX protein
GI Gastrointestinal
IC50 Inhibitory concentration at 50% effect
MM Multiple myeloma
NEO214 Perillyl alcohol conjugated to rolipram
PARP Poly [ADP-ribose] polymerase
POH Perillyl alcohol
Rp Rolipram
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